Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Gains from Investment Securities: 2019-2024

Historic Gains from Investment Securities for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Dec 2024 value amounting to -$572,000.

  • Tarsus Pharmaceuticals' Gains from Investment Securities rose 41844.00% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year increase of 818.55%. This contributed to the annual value of -$572,000 for FY2024, which is 130.99% down from last year.
  • According to the latest figures from FY2024, Tarsus Pharmaceuticals' Gains from Investment Securities is -$572,000, which was down 130.99% from $1.8 million recorded in FY2023.
  • Tarsus Pharmaceuticals' 5-year Gains from Investment Securities high stood at $2.3 million for FY2021, and its period low was -$572,000 during FY2024.
  • Moreover, its 3-year median value for Gains from Investment Securities was $215,000 (2022), whereas its average is $496,333.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first spiked by 758.60% in 2023, then crashed by 130.99% in 2024.
  • Tarsus Pharmaceuticals' Gains from Investment Securities (Yearly) stood at $726,000 in 2020, then spiked by 211.98% to $2.3 million in 2021, then crashed by 90.51% to $215,000 in 2022, then soared by 758.60% to $1.8 million in 2023, then slumped by 130.99% to -$572,000 in 2024.